BrUOG 401: A Phase 2 Study of Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
OPEN TO ACCRUAL
II
NCT04792502
aolszewski@BrownHealth.org
